AB Science
Tracked across 1 events · 7 articles · First seen May 25, 2026 · Last active Jun 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Stonegate Capital Partners has updated its coverage of AB Science's stock, setting a discounted cash flow valuation mid-point of EUR 4.25 per share. This update follows AB Science's full year 2025 results and highlights the…
Impact: AB Science's stock coverage was updated by Stonegate Capital Partners, providing a valuation mid-point of EUR 4.25 per share, which could positively influence investor perception and stock performance. The company is advancing its clinical assets masitinib and AB8939.
Jun 02, 2026 · 7 articles
100
Stonegate Capital Partners updated coverage AB ScienceStonegate Updates AB...
90
AB Science announced stock coverage update Stonegate Capital PartnersStonegate Updates AB...
70
United States — Food and Drug Administration authorized trial AB ScienceStonegate Updates AB...
60
AB Science secured insurance policyStonegate Updates AB...
NEWSDESK
Track AB Science live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard